Kazia Therapeutics (NASDAQ:KZIA) Trading Down 1.2% – Here’s What Happened

Kazia Therapeutics Limited (NASDAQ:KZIA)’s stock price fell 1.2% on Tuesday . The company traded as low as $4.78 and last traded at $4.94. 32,132 shares traded hands during trading, a decline of 92% from the average session volume of 415,323 shares. The stock had previously closed at $5.00.

Kazia Therapeutics Price Performance

The company’s 50-day simple moving average is $5.07 and its 200-day simple moving average is $4.05.

Institutional Trading of Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. MAI Capital Management purchased a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned approximately 51.66% of Kazia Therapeutics as of its most recent filing with the Securities and Exchange Commission. 30.89% of the stock is owned by institutional investors.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.